This finding is in line with the observation that, in human BPH stromal cells, the selective AR agonist DHT was able to blunt TNFα, LPS, or CD4(+)T cell-induced secretion of inflammatory/growth factors, including IL-6, IL-8, and bFGF, by blocking NF-κB nuclear translocation [86]. This evidence concerns the gene FGF2 and benign prostatic hyperplasia.